Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002369285 | SCV002661680 | uncertain significance | Cardiovascular phenotype | 2019-12-04 | criteria provided, single submitter | clinical testing | The p.E22550K variant (also known as c.67648G>A), located in coding exon 169 of the TTN gene, results from a G to A substitution at nucleotide position 67648. The glutamic acid at codon 22550 is replaced by lysine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003138219 | SCV003819067 | uncertain significance | not provided | 2019-07-24 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV003138219 | SCV004225784 | uncertain significance | not provided | 2022-04-14 | criteria provided, single submitter | clinical testing |